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Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) have become an important part of the treatment of many malignant and nonmalignant diseases. Despite a better understanding of transplant immunology and improved graft-versus-host disease (GVHD) prophylaxis as well as improvements in supportive care, there is still significant morbidity and mortality associated with HSCT. These toxic events result from organ damage induced by the preparative regimen, neutropenia predisposing to bacterial or fungal infections, or to the impaired cellular immunity that makes patients vulnerable to viral and other opportunistic infections. We and others have hypothesized that a common denominator in the pathogenesis of treatmentrelated morbidity and mortality in HSCT is the generation of reactive oxygen species (ROS), which leads to a prooxidant state. [1] [2] [3] [4] [5] [6] [7] [8] [9] This process may be mediated by free iron that is generated as a consequence of iron overload.
Iron overload is a common acute [1] [2] [3] and long-term [4] [5] [6] event associated with HSCT. Although iron is a critical element as a cofactor for proteins of the respiratory chain and for cell growth and multiplication, 10 it is potentially toxic to the host. [11] [12] [13] [14] Such toxicity is likely mediated through the conversion of free radical intermediates such as superoxide anion (O 2 À ) or hydrogen peroxide (H 2 O 2 ) to highly toxic free radicals such as hydroxyl radical (OH ). 15, 16 We will address the role of iron-generated ROS as a mediator of treatment-related toxicity in HSCT, including chronic liver disease, sinusoidal obstruction syndrome (SOS), infection and idiopathic pneumonia syndrome (IPS).
Iron chemistry
Some of the first observations on the importance of iron in biological systems came in 1894 when Fenton first recognized that trace amounts of iron as the ferrous ion [Fe(II)] could catalyze the oxidation of tartrate by H 2 O 2 .
and these authors proposed that the oxidant in the previously described Haber-Weiss reaction was the highly toxic free radical, OH , derived from iron salts ( Figure 1 ). This reaction may be more accurately written as the ironcatalyzed Haber-Weiss reaction or the superoxide-driven Fenton reaction (Figure 1) . This reaction appears to account for a part of the damage caused to living cells by excess generation of ROS. 20 
Availability of iron for catalytic reactions in vivo
In order to be biologically relevant as a mediator of tissue injury, iron must be present in a form [as Fe(II)] that makes it available to catalyze radical reactions. 21 Transferrin protects the host by leaving very little 'free' iron available in plasma for radical reactions. 22 An additional binding protein, lactoferrin, is produced by inflammatory phagocytes and is found in milk and in various body fluids, and is able to bind iron with high affinity at pH as low as 4.0. 21 This observation has led to the argument that, in the relatively acid environment at inflammatory sites, iron is released from transferrin, and its reactivity is modified by the presence of lactoferrin as a protective or modulating influence. 23 Just as transferrin and lactoferrin serve as transport proteins for iron, the large protein ferritin functions as the principal storage pool for iron. Iron stored in ferritin is not capable of catalyzing radical reactions, and is thus considered 'safe.' However, in iron-overloaded patients, the balance of free iron to bound iron changes, and free iron becomes available to catalyze free radical reactions. 24 We and others have found that in patients undergoing HSCT, there is striking and early saturation of transferrin and a rise in ferritin, leading to the development of a temporary state of 'acute plasma iron overload' (Figure 2 ). [1] [2] [3] [5] [6] [7] 25 
Iron in HSCT patients
There are several possible explanations for the sequential changes of iron status in HSCT patients, including (1) inhibition of erythropoiesis resulting from cytotoxic therapy resulting in under-utilization of iron (as might be seen in pernicious anemia), (2) bone marrow and tumor cell destruction that occurs as a consequence of high-dose therapy increasing iron levels by releasing internal iron pools from cells and (3) hepatic toxicity of cytotoxic chemotherapy and radiation leading to hepatic cell damage with subsequent further release of iron stores.
We observed that in serum samples from 88 patients undergoing autologous HSCT for various malignancies, there was a predictable significant increase in serum iron, % transferrin saturation (TS) and ferritin, which occurred 2-4 days prior to stem cell re-infusion at a time when patients were receiving either radiation or chemotherapy. 1 We hypothesized that the increased iron saturation and rise in free iron might predict for treatment-related toxicity. Du¨rken et al 2 and Sahlstedt et al 3 later described similar significant increases in serum iron and TS, as well as nontransferrin-bound iron (NTBI) in patients undergoing HSCT, and found a consistent increase over the baseline. NTBI represents free iron and is only detected in severely iron-overloaded patients. Sahlstedt et al 3 found that 88% of samples had detectable NTBI when TS was 480%, while only 8% of samples had NTBI when TS was o80%. The hepatic iron content was studied in 10 HSCT patients (two syngeneic, eight allogeneic), who died between 50 and 100 days post-transplant. 5 All patients had hepatic iron levels in the range of what is seen with hereditary hemochromatosis. There was no correlation between red cell transfusions received and liver or bone marrow iron content.
Butt and Clark 6 compared the long-term iron status of 16 HSCT recipients (six allogeneic, 10 autologous) with acute myeloid leukemia (AML) to non-HSCT patients who had been independent of all blood products for at least 3 years. They showed that HSCT patients had high ferritin levels for several years following HSCT, although the levels gradually decline over time. The presence of hemochromatosis may affect the iron status. The most common mutation is C282Y and H63D, and patients who are homozygous for C282Y or compound heterozygotes for C282Y/H63D have the highest risk for iron overload. 26, 27 The decrease in ferritin levels over time was less in patients with C282Y mutation in the study by Butt À and H2O2 may lead to DNA damage, but they have less reactivity than the highly reactive species OH . (b) This is the iron-catalyzed Haber-Weiss reaction or the superoxide-driven Fenton reaction, and results in the excess production of reactive oxygen species, thought to account for a significant part of the damage to living cells.
methotrexate. The literature on measurement of iron parameters in HSCT from the literature is summarized in Table 1 .
Measurement of pro-oxidant state in HSCT
There is a constant attack on plants and animals living in aerobic conditions by free radicals or ROS. This attack may be enhanced in the setting of HSCT by the use of radiation and chemotherapy, and by the elevated iron and fully saturated transferrin in blood. Despite this, measurement of oxidative stress has been imprecise. Pryor 30 has suggested a model for the measurement of oxidative stress. This model might include measurement of lipid peroxidation products such as malondialdehyde (MDA), thiobarbituric acid reactive substances (TBARS) in blood or urine, the measurement of DNA adducts (as a measure of DNA damage) in peripheral blood cells or urine, or the measurement of endogenous antioxidants such as catalase, and glutathione peroxidase (which degrade H 2 O 2 ), vitamin E (a free radical scavenger), SOD (which catalyzes the dismutation of superoxide anion into O 2 and H 2 O 2 ) or glutathione (an intracellular anti-oxidant) ( Figure 1 ). 31 Superoxide radicals cause extensive lipid peroxidation of the inner membrane of mitochondria, leading to destruction of the mitochondria. endogenous antioxidants. [33] [34] [35] Du¨rken et al 25 assessed antioxidant parameters in eight HSCT patients (three autologous, five allogeneic), who received busulfan/cyclophosphamide/etoposide or total-body irradiation/etoposide conditioning. They measured the total radical antioxidant parameter of plasma (TRAP), which measures the overall capacity of human plasma to inhibit radical-induced lipid peroxidation in vitro. 36 During conditioning, TRAP decreased significantly, while NTBI became detectable and accounted for 10% of total serum iron. There was a significant inverse correlation with NTBI and TRAP (r ¼ À0.59, Po0.001), indicating a pro-oxidant state. Cetin et al 9 recently documented a pro-oxidant state in patients conditioned with chemo-radiotherapy followed by autologous HSCT. Compared to baseline levels, they found significant increases in day À1 erythrocyte iron, zinc, MDA (an indicator of oxidative stress and lipid peroxidases), glutathione peroxidase and SOD.
Acute or chronic HSCT morbidity related to iron overload has been poorly studied. Transplant-related toxicity including chronic liver disease, SOS, infections and IPS have been shown to be in part related to iron overload and an increased pro-oxidant state (Figure 2 ).
Chronic liver disease
The etiology of chronic liver disease in HSCT patients is multifactorial and may be related to hepatitis, GVHD or iron overload (Table 2) . 4, 5, 8, 37, 38 Several studies have HSCT ¼ hematopoietic stem cell transplantation; PRBC ¼ packed red blood cell -indicates timing of ferritin measurement from last blood transfusion; TS ¼ percent transferrin saturation (serum iron/serum transferrin); Fe ¼ iron; NTBI ¼ non-transferrin-bound iron; Cy ¼ cyclophosphamide ¼ TBI ¼ total body irradiation; Thio ¼ thiotepa; Carbo ¼ carboplatin; Pre ¼ pre-conditioning; NR ¼ not reported; VP ¼ etoposide; normal NTBI range o0.39 mmol/l. * Po0.0001 significantly different from baseline (Pre) value. a Out of 10, nine patients with ferritin greater than 2000 mg/l received phlebotomy. 39 McKay et al 4 showed that 88% of HSCT patients were iron-overloaded a year or more posttransplant, as measured by increase in serum ferritin levels. Harrison et al 8 studied 38 allogeneic HSCT patients alive at least 3 years post-transplant and found that 10 patients had persistently elevated serum aminotransferase levels, many without known etiology and several with persistent detectable NTBI.
The importance of elevated liver enzymes in ironoverloaded HSCT patients has not been fully elucidated. Azar et al 40 found that the only parameter which predicted liver injury in 25 patients undergoing HSCT was iron overload, while Angelucci et al 38 found that the risk for progression of liver disease in patients with thalassemia was related to iron overload and hepatitis C. Tomas et al 37 found that liver disease after HSCT strongly correlated with siderosis, while Strasser et al 41 found no correlation of cirrhosis with day 80 bone marrow iron stores. The effect of iron overload on prognosis and treatment of viral hepatitis in HSCT patients has not been fully studied, 42 although in other patient populations iron overload associated with viral hepatitis is known to predict poor response to interferon and ribavirin. [43] [44] [45] Sinusoidal obstruction syndrome SOS is a treatment-related toxicity associated with autologous and allogeneic HSCT occurring in 6-54% of transplants, depending in part on the conditioning regimen ( Table 2) . 46 Listeria monocytogenes 54 and Yersinia enterocolitica infections. 55 Maertens et al 56 associated iron overload with invasive Mucormycosis in allogeneic HSCT. The mechanisms of increased susceptibility to infection with iron overload are related to impairment of phagocytosis, chemotaxis and cellular immunity. Opportunistic bacteria and fungi depend on free iron for a growth advantage. [57] [58] [59] [60] [61] Idiopathic pneumonia syndrome IPS is an important cause of morbidity and mortality in autologous and allogeneic HSCT ( Table 2) . IPS represents a group of disorders that result in interstitial pneumonitis and/or widespread alveolar injury. 62 The cumulative incidence of IPS with HSCT from recent studies is approximately 2-8%, depending on the type of transplant and conditioning regimen. [63] [64] [65] In allogeneic HSCT, IPS often occurs early, progresses rapidly, and is associated with mortality in excess of 70%. 63, 65, 66 There is increasing evidence implicating ROS and pro-inflammatory events including chemokine receptor-2/monocyte chemoattractant protein-1 interactions, high CXC-receptor-1 activity, and low macrophage inflammatory protein-1 alpha and gelsolin levels as major contributing factors to the etiology of IPS (Figure 2) . [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] Balla et al 67 found that catalytically active iron, when released from heme groups, can potentiate endothelial-cell injury and they have shown that injured lung endothelium can adapt to this iron-generated free radical attack by modulating the production of heme oxygenase and ferritin. 68 Studies of lung epithelial cells from patients with IPS have shown significantly increased levels of 8-hydroxydeoxyguanosine (a DNA adduct and a marker of oxidative DNA damage), 80 as well as cellular death through mitochondrial-mediated apoptosis. 81 Injury to alveolar epithelial cells and the underlying basement membrane activates a cascade of events culminating in some instances in acute lung injury and pulmonary fibrosis. 82 Alveolar type-1 cells, comprising nearly 95% of the alveolar surface area, are terminally differentiated and susceptible to attack by noxious agents. Alveolar epithelial cell injury is an important event in the pathogenesis of acute and chronic interstitial lung disease. 82 The alveolitis may contribute to the pathogenesis of IPS in HSCT. ROS may not only cause direct cell damage and death through the oxidation of DNA, proteins and lipids, but may also induce expression of cytokines that will amplify the IPS that occurs after HSCT. 73, [75] [76] [77] 83 Iron and survival Very few studies have assessed the role of an ironoverloaded state in the outcome of HSCT. Altes et al 7 studied the effect of TS and ferritin levels on transplantrelated mortality (TRM) and overall survival (OS) in 25 patients with hematologic malignancies transplanted (15 autologous, 10 allogeneic) after total body irradiation/ cyclophosphamide. They showed that ferritin levels 43000 mg/l on day À7 (before conditioning started) and TS of 100% on day À4 (during conditioning) were associated with inferior OS in multivariate analysis (P ¼ 0.03 and 0.02, respectively). In multivariate analysis, 100% TS (P ¼ 0.01) and increased ferritin (P ¼ 0.06) were associated with increased TRM.
Intervention
Treatment for increased oxidative stress secondary to iron overload may be directed at depletion of iron through either phlebotomy or pharmacologic chelating agents and/ or through antioxidant therapy (Figure 2 ). In patients with chronic viral hepatitis, phlebotomy has been shown to improve serum aminotransferase levels, decrease liver inflammation and inhibit the progression of liver fibrosis. [84] [85] [86] Phlebotomy has been commonly used in patients with thalassemia and persistent iron overload following allogeneic HSCT. Angelucci et al 87 showed in 41 thalassemic patients that phlebotomy (6 ml/kg blood per session) every 2 weeks was safe and effective following allogeneic HSCT. There were no cases of graft failure, protein depletion or prolonged anemia. Phlebotomy was shown to reverse iron-induced cardiac disease in thalassemic patients following HSCT. 88 The management of iron overload through chelation therapy and the associated survival and quality of life benefits have been reviewed elsewhere. [89] [90] [91] [92] [93] Intracellular iron levels may be reduced through pharmacologic chelating agents such as deferoxamine, deferiprone, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, ICL670, apotransferrin and dexrazoxane. Deferoxamine, approved by the Food Drug and Administration in 1968, is the only licensed iron-chelating product available in the United States. 93 Iron chelators decrease the redox activity of Fe(III) through their ability to bind iron, preventing the reduction of Fe(III) by superoxide and promoting the oxidation of Fe(II). 94 Deferoxamine does not chelate tightly bound iron stores (eg, hemoglobin or the cytochromes), but instead extracts iron from storage proteins with relatively weak bonds such as ferritin, transferrin and hemosiderin. 93 Iron-chelating agents have also shown antitumor and antiproliferative effects in part through interactions with important cell cycle targets such as ribonucleotide reductase, and some (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) have direct pro-oxidant activity.
90 ICL670 (4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]-benzoic acid) is an active oral iron chelator, although further efficacy and long-term safety data are needed. 91 Dexrazoxane is a heavy metal chelator that chelates intracellular iron, decreasing the ability of iron to react with superoxide anions and H 2 O 2 and preventing the production of highly toxic superoxide free radicals. It may be used as a cardioprotectant for patients receiving anthracycline chemotherapy. 95 Giardini et al 96 effectively reduced body iron stores in 18 iron-overloaded thalassemic patients after HSCT with subcutaneous deferoxamine. Li et al 97 treated 16 thalassemic patients after HSCT with deferoxamine, nine with phlebotomy and five with both, to a target ferritin of 500 mg/l. Both therapies were effective (more rapid iron depletion with deferoxamine) and were tolerated well without evidence of graft failure, including 21 patients who maintained full donor chimerism pre-and post-iron Some groups have combined erythropoietin with phlebotomy to enhance iron depletion safely. [99] [100] [101] Erythropoietin alone may reduce storage iron in part through stimulation of erythropoiesis and consequent utilization of iron stores. [102] [103] [104] Nine of 10 autograft patients in the study by Butt and Clark 6 underwent phlebotomy when they had ferritin levels over 2000 mg/l. Tomas et al 37 performed phlebotomy for 23 allogeneic HSCT patients with iron overload and chronic liver disease. The procedures were tolerated well and liver function tests improved in 21 (91%) patients. Apotransferrin is an investigational human plasma-derived product used for iron-binding therapy, 105 and has been used in clinical trials in the setting of HSCT with reduction in TS. 106 In this study, it was shown that free iron was bound by the conversion of transferrin into monoferric and diferric forms. Successful treatment of cytomegalovirus in animal tumor models with iron chelation alone (deferoxamine) 107 and Staphylococcus epidermidis with apotransferrin in HSCT patients 51 has been demonstrated.
N-acetylcysteine, glutamine (glutathione precursor) and captopril are antioxidants that have been shown to replenish glutathione redox potential and scavenge free radicals, 71, 72, [108] [109] [110] [111] but the majority of the clinical experience with these agents has been through case series and anecdotal reports (Table 3) . [112] [113] [114] [115] [116] Ringden et al 112 treated three allogeneic HSCT patients with SOS with N-acetylcysteine for 12-31 days. N-acetylcysteine treatment resulted in rapid decline of inflammatory cytokines and resolution of signs and symptoms of SOS in each patient. There have been anecdotal reports of clinical benefit for severe SOS with glutamine and vitamin E. 115 Captopril (D-3-mercato-2-methylpropanoyl-L-proline) is an orally active competitive inhibitor of angiotensinconverting enzyme, the zinc-dependent peptidase that mobilizes angiotensin I to the active vasoconstrictor angiotensin II. Captopril, a free thiol compound, is an antioxidant 122 and a free radical scavenger with SOD-like activity, 110, 111 so that it may inhibit production of ROS (Table 3 ). Though not described as an iron chelator, captopril forms complexes with zinc and copper ions, exhibiting SOD-like activity in vitro. 123 In vivo, captopril suppresses the generation of O 2 À , H 2 O 2 and OH . 124 As a scavenger of PMN-derived free radicals, captopril is equivalent to the combined effects of SOD, catalase, and allopurinol. 110 
Conclusion
We have reviewed data that suggest that iron-generated ROS may lead to a pro-oxidant state and contribute to treatment-related morbidity and mortality following autologous and allogeneic HSCT. It is clear that more research needs to be carried out in order to explore the biology and chemistry of these processes, since many of the studies reported to date are small, anecdotal and only describe phenomena. An understanding of the mechanism is lacking, and comprehensive, prospective studies have not been carried out. It remains plausible, however, based on accumulated data reviewed here, that pulmonary and hepatic injury after HSCT may be enhanced because of iron overload, and infectious complications may also be increased. Clinical trials that investigate interventions designed to prevent toxicity will require surrogate markers of tissue injury, and likely candidates include lipid peroxidation products, DNA adducts specific for ROSmediated damage (8-hydroxydeoxyguanosine) and endogenous antioxidants such as glutathione. Conditioning regimens may have to be altered and common practices such as frequent blood transfusions and liberal administration of seemingly innocuous glutathione-depleting agents (eg acetaminophen) might have to be restricted. Suggestions for monitoring iron levels and possible therapeutic options are summarized in Figure 3 . A better understanding of the physiology and molecular mechanisms involved in redox events and iron overload during and after HSCT will likely lead to reduced toxicity with improved patient outcomes.
Diagnostic testing
Therapeutic options Figure 3 Testing and therapeutic options for HSCT-related iron overload.
Iron and oxidative stress AM Evens et al
